Open-label Patient Continuation of DX-88 (Ecallantide) for acute Hereditary Angioedema (HAE) Attacks
Description of Research
The purpose of this study is to determine the efficacy and safety of an experimental drug, DX-88, in the treatment of acute attacks of hereditary angioedema (HAE) in patients who are not eligible to enroll in any other DX-88 protocol.
Age 10 or older
History of HAE
Additional screening criteria